Skip to content
The Nexus
HEALTHJul 1 · 09:25 UTCFORTUNELily Mae Lazarus

Eli Lilly just placed a $40 million bet on the next injectable boom

Eli Lilly invested $40 million in Absci, an AI-driven drug company developing ABS-201, an injectable antibody targeting androgenetic alopecia and endometriosis. The investment coincided with Absci releasing positive Phase 1 safety data, and both companies aim to leverage direct-to-consumer strategies and AI-designed drugs to disrupt the injectable market.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Eli LillyorganizationAbsciorganizationABS-201topicandrogenetic alopeciatopicendometriosistopicGLP-1topicIsomorphic LabsorganizationEarendil Labsorganization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting